BIA Networking Lunch - Stevenage


Register today for another popular networking lunch, hosted by Stevenage Bioscience Catalyst. This is a great opportunity to hear from local members, meet new business contacts and grab a bite to eat. We are excited to be showcasing members the Stevenage region.


12.00:  Lunch and networking

13.00:  Steve Bates, CEO, BIA 

13.10:  Sally Ann Forsyth, CEO, Stevenage Bioscience Catalyst 

13.20:  Company presentations
Representatives from Freeline Therapeutics, LifeArc, and LifT Biosciences will join us to give short presentations on their work and recent developments.

14.00:  Networking  - tea, coffee, and biscuits provided

14.30:  Close


Dr Sally Ann Forsyth

Chief Executive Officer

Stevenage Bioscience Catalyst

Sally Ann was appointed as Chief Executive Office of Stevenage Bioscience Catalyst in March 2018 to lead it through its next phase of expansion.

Prior to taking up her role as CEO at Stevenage Bioscience Catalyst, Dr Forsyth was Director of Harwell Oxford (Science and Technology Facilities Council), Colworth Science Park (Unilever) and CEO for Norwich Research Park (BBSRC, NNUH and UEA), leading their transformation from national research centres in to internationally recognised science parks.

Sally Ann began her career as a management trainee with Unilever holding a range of senior roles across technology licensing, open innovation, strategic alliance management and venture capital investment before joining Goodman International property group as Director of Science Parks.

She has a PhD in Molecular Biology from the University of Cambridge and is a qualified Chartered Global Management Accountant.

Jane Whitrow

Vice President, Business Operations

Freeline Therapeutics

Jane is a Chartered Accountant who brings specialist experience of working with small and medium-sized technology businesses.

She joined Freeline after seven years at IXICO, where she was responsible for fundraising, forecasting, financial reporting, investor relations, HR, IT, legal, facilities, Quality and Company Secretarial. Here she was part of the management team that acquired Phytopharm, and the subsequent listing on the AIM market. Before that, she worked for a variety of high-tech and start-up companies, including Cambridge Biostability, Novacta Biosystems and BioSyntha.

Jane also spent five years at the biotech venture capitalist Merlin Ventures (latterly Merlin BioSciences), becoming Finance Director. She trained as an accountant with KPMG focusing on small and medium-sized technology businesses. Jane has a BSc from the University of Manchester and a PhD in Plant Genetics from the University of Birmingham

Justin Bryans

Executive Director, Drug Discovery


Justin trained at the Universities of York and Oxford and has worked as a medicinal chemist for over 25 years in Biotech and Pharma, including Parke-Davis and Pfizer, delivering a number of clinical candidates. He joined LifeArc in 2005 where he currently leads the drug discovery team collaborating with academics on cutting edge science to deliver proof of concept and develop potential drugs for diseases of high unmet need. Justin teaches on drug discovery at QMUL, UCL and the Wellcome Trust. He also sits on the Drug Discovery Committee for Cancer Research UK and is a Fellow of the Royal Society of Chemistry.

Alex Blyth, BSc (Econ) BSc (Bio)

CEO and Founder

LifT Biosciences

Alex is a serial entrepreneur who has built and sold two companies. Biopharma strategy and market access consultant with 16 years’ experience in bringing to market >50 mostly novel biopharma assets, inc. Gleevec, Afinitor, Blincyto & T-VEC for clients including Pfizer, Allergan, abbVie, Amgen, Shire, Takeda, GSK & Sanofi.

He set-up the company after losing his mother to pancreatic cancer and seeing a new way to beat cancer. LIfT Biosciences is a Biotech bringing to market a 1st in class allogeneic innate cell therapy called Neutrophil Only Leukocyte Infusion Therapy (N-LIfT). N-LIfT has the game-changing potential to destroy all solid tumours irrespective of mutation or strain. N-LIfT uses a special type of N1a neutrophil with special cancer killing and immune recruitment capabilities. Our vision is to develop the world’s first cell bank of mass produced ‘cancer killing neutrophils’ to deliver a portfolio of immuno-oncology cell therapies for curing all solid tumours.


Stevenage Bioscience Catalyst
Gunnels Wood Rd


Free for members and non-members

By registering to this event you accept our Terms & Conditions

Thank you to our event host


BIA Annual Supporters